Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2021-12-16 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
中源协和细胞基因工程股份有限公司详式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled "详式权益变动报告书" which translates to "Detailed Equity Change Report." It is issued by a listed company and details the change in shareholding and voting rights by an information disclosure obligor and its concerted parties. The content includes detailed information about the parties involved, their shareholding structure, control relationships, business scope, and plans related to the equity change. It references relevant Chinese securities laws and regulations governing equity changes and disclosures. The document is lengthy (15,000 characters) and contains substantive information about the equity change, not just an announcement or a brief summary. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. It is not an annual report, audit report, earnings release, or any other category. Therefore, the correct classification is MRQ with high confidence.
2021-12-16 Chinese
中源协和细胞基因工程股份有限公司关于控股股东签署表决权委托协议暨控制权发生变更的提示性公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement regarding a change in the controlling shareholder and actual control of the company due to a voting rights entrustment agreement. It includes specifics about shareholding percentages, parties involved, and the impact on control structure. There is no financial data, earnings information, or report publication mentioned. The content focuses on ownership and control changes, which aligns with announcements about changes in control or management. This fits best under the category of Board/Management Information (MANG), as it concerns changes in the company's controlling shareholders and actual controllers, which is a form of senior management/board-related information. The document is not a full report, call transcript, or regulatory filing, but a formal announcement of control change.
2021-12-14 Chinese
北京国枫律师事务所关于中源协和细胞基因工程股份有限公司2021 年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, and legality of a company's 2021 first extraordinary general meeting of shareholders. It details the meeting's notice, attendance, voting procedures, and results, confirming compliance with laws and company regulations. It does not contain financial statements or financial performance data, nor is it a report or announcement of financial results. Instead, it is a legal opinion related to a shareholders' meeting. This type of document is best classified under Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to the official voting results and legal validation of a shareholders' meeting.
2021-12-10 Chinese
中源协和细胞基因工程股份有限公司2021年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2021 first extraordinary general meeting of shareholders of the company. It includes details about the meeting date, attendance, voting results, and legal witness statements. The content focuses on the voting outcomes and procedural compliance rather than presenting a full report or financial statements. The document length is short (1618 characters) and it is clearly an announcement of voting results from a shareholders meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-12-10 Chinese
中源协和细胞基因工程股份有限公司关于使用闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding the use of idle raised funds to temporarily supplement working capital. It details the amount of funds raised, the intended use of the funds, approvals by the board and supervisory committee, and opinions from independent directors and sponsors. The document does not contain financial statements or detailed financial performance data but is a regulatory announcement about the use of capital raised. It is not a full financial report, audit report, or earnings release. The document fits the category of Capital/Financing Update (CAP) as it concerns the use and management of raised capital funds.
2021-12-08 Chinese
东兴证券股份有限公司关于中源协和细胞基因工程股份有限公司使用闲置募集资金暂时补充流动资金之核查意见
Capital/Financing Update Classification · 95% confidence The document is a verification opinion from an independent financial advisor (Dongxing Securities) regarding the use of idle raised funds by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. to temporarily supplement working capital. It references regulatory guidelines on the management and use of raised funds, details the raised funds and their intended projects, and confirms the approval by the company's board and supervisory committee. The document is a formal verification or advisory opinion related to the use of capital raised through a previous financing event, not a full financial report or earnings release. It does not contain financial statements or detailed financial data but rather a compliance and advisory statement. This fits the category of a Capital/Financing Update (CAP) as it relates to the use and management of raised capital funds and their temporary allocation.
2021-12-08 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.